Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and anandamide

3,4-dihydroxyphenylacetic acid has been researched along with anandamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Miguel, R; Fernández-Ruiz, JJ; González, S; Lastres-Becker, I; Makriyannis, A; Ramos, JA; Romero, J; Villanua, MA1
De Laurentiis, A; Fernández Solari, J; McCann, SM; Mohn, C; Rettori, V; Scorticati, C; Seilicovich, A; Vissio, P1
de Lago, E; de Miguel, R; Fernández-Ruiz, J; Lastres-Becker, I; Ramos, JA1
Baker, D; Cabranes, A; de Lago, E; Fernández-Ruiz, J; López-Rodríguez, M; Ortega-Gutiérrez, S; Pryce, G; Ramos, JA1

Other Studies

4 other study(ies) available for 3,4-dihydroxyphenylacetic acid and anandamide

ArticleYear
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.
    Life sciences, 1999, Volume: 65, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Arachidonic Acids; Basal Ganglia; Biological Transport, Active; Carrier Proteins; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Endocannabinoids; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Male; Neurosecretory Systems; Pituitary-Adrenal System; Polyunsaturated Alkamides; Prolactin; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase

1999
The effect of anandamide on prolactin secretion is modulated by estrogen.
    Proceedings of the National Academy of Sciences of the United States of America, 2003, Feb-18, Volume: 100, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Arachidonic Acids; Dopamine; Endocannabinoids; Estrogens; Female; Hypothalamus; Male; Neurons; Ovariectomy; Polyunsaturated Alkamides; Prolactin; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug

2003
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
    Brain research, 2004, May-08, Volume: 1007, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Modulators; Capsaicin; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Interactions; Electrochemistry; Endocannabinoids; In Vitro Techniques; Ion Channels; Male; Motor Activity; Neurons; Polyunsaturated Alkamides; Potassium; Rats; Rats, Wistar; Receptors, Drug; Stereotyped Behavior; TRPV Cation Channels; Tyrosine 3-Monooxygenase

2004
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Exploratory Behavior; Furans; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Huntington Disease; Male; Malonates; Movement Disorders; Multiple Sclerosis; Nitro Compounds; Oxidopamine; Polyunsaturated Alkamides; Propionates; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase

2006